Ironwood Pharmaceuticals, Inc. (IRWD) Stock Analysis
Ironwood is a highly profitable LINZESS cash-flow story racing to build an apraglutide rare-disease bridge before the 2029 generic cliff.
Overview
Ironwood has evolved into a profitable commercial-stage GI biotech built around LINZESS, whose U.S. economics are powered by AbbVie’s commercial infrastructure and a 50/50 profit-share. After 2025 pricing volatility, the company entered 2026 with a strong reset, record sales guidance, and renewed profitability. The investment story hinges on using LINZESS cash flows before the 2029 generic cliff to deleverage and fund apraglutide, a potentially best-in-class once-weekly therapy for SBS-IF that could become the company’s next growth engine.